Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date April 26, 2022 · Filed April 26, 2022
Section 16 reporting ended · disclosed 2022-04-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,734 |
Reported balance
Holding disclosure · report date 2022-04-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 56,734 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2022 Filed Apr 4, 2022 20:46 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,769 | $25.88 | $45,781.72 |
DisclosureSEC source: 0001853654-22-000006 · edgardoc.xml · nonDerivative · entry 2 Santa Eric · CIK 0001853654 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,734 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:46 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,207 | $25.88 | $31,237.16 |
DisclosureSEC source: 0001853654-22-000006 · edgardoc.xml · nonDerivative · entry 1 Santa Eric · CIK 0001853654 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,503 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 1, 2022. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 21:03 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 19,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001853654-22-000004 · edgardoc.xml · nonDerivative · entry 1 Santa Eric · CIK 0001853654 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,710 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 22:24 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 24,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001853654-22-000002 · edgardoc.xml · nonDerivative · entry 1 Santa Eric · CIK 0001853654 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,472 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on April 1, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on April 1, 2022, 25% on April 1, 2023, 25% on April 1, 2024, and 25% on April 1, 2025. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 15:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 16,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001853654-21-000004 · edgardoc.xml · nonDerivative · entry 1 Santa Eric · CIK 0001853654 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,420 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.